Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (25 July 2022) | Viewed by 14294

Special Issue Editors

Dr. Sara Ramella

E-Mail Website
Guest Editor
Radiation Oncology, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy
Interests: integration of radiotherapy; chemotherapy drugs and biological drugs into the treatment of neoplasms of the esophagus, liver, biliary tract, pancreas and rectum
Dr. Alessandro Coppola

E-Mail Website1 Website2
Guest Editor
Department of General Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy
Interests: pancreatic cancer; pancreatic surgery; hepatobiliary cancers; liver surgery; liver transplant; surgical oncology
Special Issues, Collections and Topics in MDPI journals
Dr. Vincenzo La Vaccara

E-Mail Website1 Website2
Guest Editor
PhD. Department of General Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy
Interests: pancreatic cancer; pancreatic cyst; pancreatic surgery; surgical oncology; colorectal surgery early detection
Dr. Michele Fiore

E-Mail Website1 Website2
Guest Editor
Radiation Oncology, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy
Interests: integration of radiotherapy; chemotherapy drugs and biological drugs into the treatment of neoplasms of the head and neck, liver, biliary tract and pancreas

Special Issue Information

Dear Colleagues,

Hepatobiliary and pancreatic cancers represent two of the deadliest malignances. The aggressive behavior of the diseases and the often-advanced stages at the moments of diagnosis are the main causes for the high mortality rate of these patients. However, in recent years, several advances have been made in the management of this family of diseases. The improvement of surgical techniques, more targeted chemo- and radiotherapy, and radiological and endoscopic techniques are at the core of the research in the hepatobiliary and pancreatic field.

Multidisciplinary approaches represent one of the most powerful weapons against this group of diseases. In fact, the adoption of this type of approach makes it possible to adopt increasingly advanced and complex strategies that allow obtaining increasingly encouraging results.

You are kindly invited to share your knowledge, perspectives, and recent advances in the management of hepatobiliary and pancreatic malignancies in this Special Issue of the Journal of Clinical Medicine.

Prof. Sara Ramella
Dr. Alessandro Coppola
Dr. Vincenzo La Vaccara
Dr. Michele Fiore
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pancreatic cancer
  • Liver cancer
  • Biliary tract cancer
  • Liver surgery
  • Pancreatic surgery
  • Transplant surgery
  • Metastases
  • HPB oncology
  • Radiotherapy
  • Immunotherapy
  • Chemotherapy
  • Interventional radiology
  • Interventional endoscopy
  • Early detection
  • Mininvasive surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

4 pages, 201 KiB  
Editorial
Special Issue “Hepatobiliary and Pancreatic Cancers: Novel Strategies for of Diagnosis and Treatments”
by Alessandro Coppola, Michele Fiore, Vincenzo La Vaccara, Tommaso Farolfi, Damiano Caputo and Sara Ramella
J. Clin. Med. 2022, 11(13), 3849; https://doi.org/10.3390/jcm11133849 - 2 Jul 2022
Cited by 2 | Viewed by 1173
Abstract
In recent years, hepato-pancreato-biliary (HPB) cancers have been increasing their incidence [...] Full article
(This article belongs to the Special Issue Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments)

Research

Jump to: Editorial

12 pages, 1722 KiB  
Article
Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
by Siyu Liu, Liyang Sun, Lanqing Yao, Hong Zhu, Yongkang Diao, Mingda Wang, Hao Xing, Wan Yee Lau, Mingcheng Guan, Timothy M. Pawlik, Feng Shen, Min Xu, Xiangmin Tong and Tian Yang
J. Clin. Med. 2022, 11(17), 5075; https://doi.org/10.3390/jcm11175075 - 29 Aug 2022
Cited by 16 | Viewed by 2986
Abstract
Background and Aim: Alpha-fetoprotein (AFP), a lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), is a protein that is induced by vitamin K deficiency or antagonist-II (PIVKA-II) that has been clinically used as a serum biomarker for early detection and diagnosis of hepatocellular carcinoma [...] Read more.
Background and Aim: Alpha-fetoprotein (AFP), a lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), is a protein that is induced by vitamin K deficiency or antagonist-II (PIVKA-II) that has been clinically used as a serum biomarker for early detection and diagnosis of hepatocellular carcinoma (HCC). Diagnostic performance of each serum biomarker alone, or their combinations for the detection of hepatitis C virus (HCV)-associated HCC were compared. Methods: Serum AFP, AFP-L3, and PIVKA-II levels were evaluated in patients with HCV-associated HCC, and those with chronic HCV infection without HCC (HCV-controls). The areas under the curve (AUC), sensitivity, and specificity were compared to identify the diagnostic performance of each serum HCC biomarker alone or in combination. Results: Overall, 172 HCV controls and 105 patients with HCV-associated HCC were enrolled. The AFP, AFP-L3, and PIVKA-II levels were significantly increased among patients with HCV-associated HCC when compared with HCV patients without HCC (p < 0.001). When these biomarkers were analyzed individually, PIVKA-II revealed the best predictive performance (AUC: PIVKA-II 0.90 vs. AFP 0.80 vs. AFP-L3 0.69, p < 0.001). In evaluating the combinations of any two biomarkers, the best predictive performance was found in PIVKA-II + AFP (0.93 vs. AFP + AFP-L3 0.78, p = 0.001; and PIVKA-II + AFP-L3 0.89, p < 0.001), which had no difference compared to the predictive performance of the combination of all three serum biomarkers (AFP + AFP-L3 + PIVKA-II 0.93, p = 0.277). Similar results were identified in the subgroups of patients with HCV-induced cirrhosis, and among patients with early-stage HCC defined by BCLC and TNM staging. Conclusions: The addition of the PIVKA-II test to routine AFP test maybe provide a more suitable biomarker approach to detect HCV-induced HCC in patients with HCV infection undergoing HCC surveillance. Full article
(This article belongs to the Special Issue Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments)
►▼ Show Figures

Figure 1

8 pages, 256 KiB  
Article
Two-Phase MDCT Protocol for the Screening of Small Hepatocellular Carcinoma
by Anita Paisant, Jérôme Boursier, Djamel Dabli, Jérôme Lebigot, Frédéric Oberti, Sophie Michalak, Valérie Vilgrain and Christophe Aubé
J. Clin. Med. 2022, 11(15), 4282; https://doi.org/10.3390/jcm11154282 - 22 Jul 2022
Cited by 2 | Viewed by 1446
Abstract
Screening programmes for cirrhotic patients are based on ultrasound (US) examinations at 6-month intervals, but a US sensitivity of 47% has recently been reported. The aim of this study was to evaluate a two-phase MDCT protocol in terms of hepatic nodule detection within [...] Read more.
Screening programmes for cirrhotic patients are based on ultrasound (US) examinations at 6-month intervals, but a US sensitivity of 47% has recently been reported. The aim of this study was to evaluate a two-phase MDCT protocol in terms of hepatic nodule detection within a hepatocellular carcinoma (HCC) screening situation and to evaluate a reduction in irradiation dose for the 6-monthly checks compared to the classic four-phase protocol. In total, 373 patients with 498 nodules that were suspected to be HCC and ranged from 10 to 30 mm in size were prospectively included. All patients underwent four-phase MDCT with an unenhanced phase, arterial phase (AP), portal phase (PP) and delayed phase (DP). The cumulative irradiation from the repeated 6-monthly MDCT protocol was calculated. Of the 498 nodules, only 4 (0.008%) were only seen in the PP and not in the AP or AP. Of the 319 HCC nodules, 270 (84.6%) had AP hyperenhancement, while 115 had washout in the PP and 224 had washout in the DP. Overall, 222 of the 224 (99.1%) HCC nodules with typical features were seen in the AP and DP. The dose reduction was estimated at 55.4% when using the two-phase protocol (AP and DP). The cumulative irradiation of the two-phase protocol, which was performed every 6 months over 5 years, was 96.5 mSv. MDCT with the two-phase protocol could offer an alternative to ultrasound screening with an interesting risk–benefit trade-off. Full article
(This article belongs to the Special Issue Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments)
10 pages, 2149 KiB  
Article
Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality
by Sebastian Krug, Marko Damm, Jakob Garbe, Senta König, Rosa Lynn Schmitz, Patrick Michl, Jörg Schrader and Anja Rinke
J. Clin. Med. 2021, 10(14), 3023; https://doi.org/10.3390/jcm10143023 - 7 Jul 2021
Cited by 10 | Viewed by 3013
Abstract
The systemic treatment of patients with pancreatic neuroendocrine tumors is based on placebo-controlled trials and long-established chemotherapy approaches. In addition, peptide receptor radionuclide therapy (PRRT) was approved as a parallel approach for pancreatic neuroendocrine tumors (NET), in addition to small bowel NET, after [...] Read more.
The systemic treatment of patients with pancreatic neuroendocrine tumors is based on placebo-controlled trials and long-established chemotherapy approaches. In addition, peptide receptor radionuclide therapy (PRRT) was approved as a parallel approach for pancreatic neuroendocrine tumors (NET), in addition to small bowel NET, after the NETTER-1 trial. The current ESMO and NCCN guidelines attempted to describe treatment algorithms for pancreatic NET based on the current data. In our survey, we recorded therapy decisions for the first- until the third-line of therapy in German-speaking countries (Germany, Austria, and Switzerland) using fictional case reports and discussed these in the context of the current ESMO guidelines. Compared with the recommendations of the guidelines, PRRT was used more frequently and earlier. In patients with NET G1/G2 Ki-67 < 10%, the therapy algorithm consisting of somatostatin analogs (SSA)-PRRT-targeted therapy is a relevant approach. In clinical situations where chemotherapy is primarily used (remission pressure, Ki-67 > 10%), second-line PRRT was found acceptance and was often considered prior to targeted therapies. Despite the lack of prospective controlled trials, our study demonstrated the pivotal impact of PRRT. Therefore, further studies should compare PRRT with chemotherapy in pancreatic NETs in different clinical settings in first- and second-line approaches. Full article
(This article belongs to the Special Issue Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments)
►▼ Show Figures

Figure 1

13 pages, 1199 KiB  
Article
Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study
by Mohammad Inamul Haq, Thomas M. Drake, Tee Lin Goh, Asma Ahmed, Ewan Forrest, Stephen Barclay, Ruth Gillespie, Mathew Priest, Jeff Evans, Janet Graham, Stuart Ballantyne, Donald C. McMillan, Peter C. Hayes, Thomas G. Bird and Adrian J. Stanley
J. Clin. Med. 2021, 10(13), 2770; https://doi.org/10.3390/jcm10132770 - 24 Jun 2021
Cited by 10 | Viewed by 2519
Abstract
Introduction: Surveillance for hepatocellular carcinoma (HCC) is recommended by national and international guidelines. However, there are no trial data on whether surveillance improves clinical outcomes in a UK cirrhosis population of mixed aetiology. Our aim was to determine the impact of, and adherence [...] Read more.
Introduction: Surveillance for hepatocellular carcinoma (HCC) is recommended by national and international guidelines. However, there are no trial data on whether surveillance improves clinical outcomes in a UK cirrhosis population of mixed aetiology. Our aim was to determine the impact of, and adherence to, surveillance on overall survival. Methods: We prospectively collected data on consecutive patients diagnosed with HCC between January 2009 and December 2015 at two large UK centres. We assessed outcomes depending on whether they had been entered into an HCC surveillance programme, and if they had adhered to that. Results: Out of 985 patients diagnosed with HCC in this study, 40.0% had been enrolled in a surveillance programme. Of these, 76.6% were adherent with surveillance and 24.4% were not. Adherence to surveillance was significantly associated with improved overall survival, even when accounting for lead-time bias using different approaches (HR for 270 days lead-time adjustment 0.64, 0.53 to 0.76, p < 0.001). Conclusions: When adjusted for lead-time bias, HCC surveillance is associated with improved overall survival; however, the beneficial effect of surveillance on survival was lower than reported in studies that did not account fully for lead-time bias. Full article
(This article belongs to the Special Issue Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments)
►▼ Show Figures

Figure 1

12 pages, 1878 KiB  
Article
Different Biliary Microbial Flora Influence Type of Complications after Pancreaticoduodenectomy: A Single Center Retrospective Analysis
by Alessandro Coppola, Vincenzo La Vaccara, Tommaso Farolfi, Michele Fiore, Chiara Cascone, Sara Ramella, Silvia Spoto, Massimo Ciccozzi, Silvia Angeletti, Roberto Coppola and Damiano Caputo
J. Clin. Med. 2021, 10(10), 2180; https://doi.org/10.3390/jcm10102180 - 18 May 2021
Cited by 14 | Viewed by 1993
Abstract
Background: Bacterobilia is associated with postoperative morbidity after pancreaticoduodenectomy (PD), mostly due to infectious complications. The aim of this study was to investigate the prevalence of bacteria species isolated from intraoperative biliary cultures, and related complications after PD. Methods: An ANOVA test was [...] Read more.
Background: Bacterobilia is associated with postoperative morbidity after pancreaticoduodenectomy (PD), mostly due to infectious complications. The aim of this study was to investigate the prevalence of bacteria species isolated from intraoperative biliary cultures, and related complications after PD. Methods: An ANOVA test was used to assess the prevalence of isolated bacterial species and postoperative complications. The odds ratio was computed to evaluate the association between biliary cultures and each complication, Endoscopic Retrograde CholangioPancreatography (ERCP) and each complication, ERCP and biliary cultures, Delayed Gastric Emptying (DGE) and Postoperative Pancreatic Fistula (POPF). Results: Positive biliary cultures were found in 162/244 (66%) PDs. Different prevalences of polymicrobial biliary culture were detected in patients with postoperative complications. In SSIs, a significant prevalence of biliary culture positive for E. coli, Klebsiella pneumoniæ and Enterococcus fæcalis (p < 0.001) was detected. Prevalences of polymicrobial biliary cultures with Escherichia coli, Klebsiella pneumoniæ, Enterococcus fæcalis and Enterococcus fæcium were significantly associated with POPF (p < 0.001). Biliary culture positive for Escherichia coli, Enterococcus fæcalis and Enterococcus fæcium showed a higher prevalence of intra-abdominal collection and DGE (p < 0.001). Notably, Escherichia coli was significantly associated with DGE as a unique complication (OR = 2.94 (1.30–6.70); p < 0.01). Conclusions: Specific prevalences of polymicrobial bacterobilia are associated with major complications, while monomicrobial Escherichia coli bacterobilia is associated with DGE as a unique complication after PD. Full article
(This article belongs to the Special Issue Hepatobiliary and Pancreatic Cancers: Novel Strategies of Diagnosis and Treatments)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop